KPV is a three‑amino‑acid fragment of α‑MSH that users take mainly for skin conditions, wound healing, systemic inflammation, pain, and gut‑related issues. The community most often runs 500 µg daily, with doses ranging from 50 µg to 30 mg, while clinician‑guided protocols suggest 200–500 µg per day (often split BID) for 6–12 weeks. The only clear trade‑off is that it has no FDA‑approved indication, so all human use is off‑label or compounded; side‑effect reports are limited, with occasional nausea, injection‑site irritation, occasional fluid retention, rare flushing, and consistently noted changes in sleep or vivid dreams.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The only published data for KPV come from animal‑only, preclinical mechanistic studies, so human evidence is absent. Across the literature there is a single mapped indication and no registered or completed human trials, meaning the peptide has no demonstrated clinical efficacy. The lack of any human‑focused research—no blinded studies, no sponsor‑driven programs, and no trial results—signals that its therapeutic claims remain unverified.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 23 out-of-stock offers not shown
How KPV is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
According to the two sources, clinician practice uses KPV topically at 200–500 mcg twice daily, with 500 mcg cited as the typical dose.
Most community users take KPV without a set schedule (≈24 reports), while about half that number dose daily (≈20 reports) usually at 500 mcg; a lone report notes twice‑daily dosing, and only two describe a 5 days‑on/2 days‑off cycle.